Health

Novel endometriosis diagnostic tools emerge amid persistent delays in global medical care

Diagnostic tests undergoing evaluation abroad aim to reduce yearslong waits for care, though US approval remains pending.

Updated Sep 5, 2026 · 12:19 UTC1 reports

The short version

Endometriosis affects approximately 1 in 10 women globally, but patients frequently wait a decade or longer for an accurate diagnosis.[Associated Press]
Emerging tools like the EndoSure abdominal sensor and Endotest saliva analysis are currently undergoing a proposed three-year trial under draft guidance in the UK.[Associated Press]
Neither test is currently approved by the US FDA, though developers are pursuing clearance and certified laboratory distribution pathways.[Associated Press]
Medical professionals caution that new testing technologies will serve as auxiliary aids rather than fully replacing established diagnostic procedures.[Associated Press]

Endometriosis affects approximately 1 in 10 women globally, with patients often waiting a decade or more for diagnosis due to symptom normalization and diagnostic overlap.[Associated Press]
Draft guidance in the UK recommends the NHS evaluate EndoSure and Endotest over a three-year period to gather performance data.[Associated Press]
EndoSure is preparing a formal FDA application, while Ziwig is seeking to offer Endotest through certified US laboratories without direct FDA approval.[Associated Press]

The extent to which new diagnostic tools will successfully integrate into standard care pathways and reduce overall diagnosis timelines remains under active trial evaluation.[Associated Press]
The timeline and regulatory outcome for US FDA approval of EndoSure and certified laboratory access for Endotest remain undetermined.[Associated Press]

Outlet counts describe coverage, not independent confirmation. Reports may share a wire service or original source.